Genelux Q1 EPS Decreased by Brookline Capital Management

Genelux Co. (NASDAQ:GNLX) – Analysts at Brookline Capital Management reduced their Q1 2025 EPS estimates for Genelux in a note issued to investors on Monday, March 31st. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings of ($0.23) per share for the quarter, down from their previous estimate of ($0.20). The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux’s Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.86) EPS.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09).

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Genelux in a research report on Monday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Genelux has an average rating of “Buy” and an average price target of $18.25.

Genelux Stock Down 2.3 %

Shares of NASDAQ:GNLX opened at $2.54 on Thursday. Genelux has a 52-week low of $1.60 and a 52-week high of $5.89. The stock has a market cap of $88.21 million, a price-to-earnings ratio of -2.67 and a beta of -1.41. The business has a 50-day moving average price of $4.04 and a 200-day moving average price of $3.10.

Hedge Funds Weigh In On Genelux

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in Genelux by 39.7% during the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after acquiring an additional 89,854 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Genelux by 51.4% during the 4th quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock worth $368,000 after purchasing an additional 52,958 shares during the period. LPL Financial LLC increased its holdings in shares of Genelux by 72.3% during the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock valued at $222,000 after purchasing an additional 39,516 shares in the last quarter. LifeSteps Financial Inc. lifted its stake in shares of Genelux by 11.1% in the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company’s stock valued at $205,000 after purchasing an additional 8,715 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Genelux during the third quarter worth $59,000. Institutional investors and hedge funds own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.